Non-Statin Lipid-Lowering Agents (Last modified May 2016)
|
|
- Edmund Washington
- 6 years ago
- Views:
Transcription
1 PL Detail-Document # This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER July 2015 Non- Lipid-Lowering Agents (Last modified May 2016) s are the lipid-lowering agents of choice because they have by far the most, and most robust, evidence for reducing cardiovascular events, including death. 25,49 Non-statins are no longer recommended for routine use. 25,49 When deciding to start or continue a non-statin, consider the following: The addition of a non-statin to a statin has not been proven to further reduce cardiovascular mortality. 1,25,30,49 Despite IMPROVE-IT, the FDA denied the expanded indication for morbidity and mortality benefits for ezetimibe. 65 Adding a non-statin to achieve a specific LDL goal could result in reduction of the statin to a suboptimal dose. 49 Reinforce statin adherence and lifestyle changes, and check for secondary causes before adding a non-statin. 25,49 For patients who cannot tolerate the recommended statin dose or who do not achieve the expected statin response (e.g., 50% LDL reduction with high-intensity statin) and are high-risk at baseline, consider adding a non-statin. 25,49 Consider adding ezetimibe to a moderate-intensity statin in high-risk patients, especially those with a recent ACS. 30 There s no proof that adding other non-statins (fibrates, etc) to a statin improves outcomes, and niacin worsens glycemic control. 1,32 Consider adding a PCSK9 inhibitor in high-risk patients with extremely elevated LDLs (e.g., familial hypercholesterolemia) Consider a bile acid sequestrant, gemfibrozil, or niacin for patients who cannot tolerate a statin. 1,7,21,24 Do not add gemfibrozil to a statin due to myopathy risk. 49 Consider omega-3 fatty acids, fenofibrate, or niacin if TG 500 mg/dl (about 5 mmol/l), or even approaching 1000 mg/dl (about 10 mmol/l). 38,39 However, there s no good evidence that lowering triglycerides reduces CV events or prevents pancreatitis. The chart below provides lipid effects, outcomes, and cost information for the non-statins. (Information in the chart may differ from product labeling). For specifics on lowering triglycerides see our PL Detail-Document, Strategies for Lowering Triglycerides; for more information on the lipid-lowering potential of individual statins in our PL Chart, Characteristics of the Various s. Abbreviations: ACS = acute coronary syndrome; CV = cardiovascular; CVD = cardiovascular disease; ER = extended-release; GI = gastrointestinal; HDL = highdensity lipoprotein; HeFH = heterozygous familial hypercholesterolemia; HoFH = homozygous familial hypercholesterolemia; IR = immediate release; LDL = lowdensity lipoprotein; PCSK9 = proprotein convertase subtilisin/kexin type 9; SR = sustained release; SubQ = subcutaneous; TG = triglycerides Alirocumab d (Praluent [U.S.]) Continued LDL : 40% to 60%. 52,56,63 (Regardless of statin use.) See Lipid Effects column. Post-hoc analysis suggests alirocumab in combination with maximally Very expensive. Consider as monotherapy (statinintolerant patients) or added to maximally U.S.: $1120 (75 mg/two weeks).
2 (PL Detail-Document #310703: Page 2 of11) Alirocumab, continued (PCSK9 inhibitor) tolerated statin doses may reduce major CV events in high-risk patients. Further data are needed to confirm [Level B]. 55 tolerated statin (with or without ezetimibe) in patients with HeFH or clinical CVD requiring additional LDL lowering. 52 No adjustment needed with mild to moderate renal or hepatic impairment. No safety data available with severe renal or hepatic impairment. 52 Administer via SubQ injection (allow to reach room temperature before injecting). 52 No long-term safety data. Bezafibrate (Bezalip SR, generic bezafibrate SR, generic immediaterelease bezafibrate); (Canada only) (Fibric acid) LDL : 6% to 21% (400 mg). 35,36 HDL : 15% to 25% (400 mg). 35,36 TG : 25.1% to 42% (400 mg). 35,36 1.1% (400 mg) % (400 mg). 36 Further TG : 31.7% (400 mg). 36 Secondary prevention: prevents composite endpoint of MI and sudden death in a subgroup with TG 200 mg/dl or higher. No increase in non-cv death. 37 First-line option for TG >10 mmol/l. 39 Option for TG 5 to 10 mmol/l. 39 Option for low HDL. 39 Reversible increase in serum creatinine. 33 Requires renal dose adjustment. 33,b Limited data with statins. Canada: $75.43 (Bezalip SR) (400 mg/day).
3 (PL Detail-Document #310703: Page 3 of11) Cholestyramine (Questran, Questran Light [U.S.; brands no longer available], Olestyr [Canada] (Bile acid sequestrant) LDL : 9% (4 g to 8 g/day); 1 21% (16 g to 20 g/day); 1 23% to 28% (>20 g/day). 1 HDL : 4% to 8% (16 to 24 g/day). 1 TG : 11% to 28% (4 g to 24 g/day). 1 about 10% (8 g) to about 20% (24 g). 4,5 0% to 10%. 3,4 Primary prevention, men: reduces need for bypass, and combined endpoint of coronary heart disease, death, and nonfatal MI (NNT = 59 for 7 years) [Level A]. 6,14 Secondary prevention, men: with diet, reduces cardiac events vs usual care (not placebo-controlled; events not a primary outcome)[level B]. 7 Slows progression and increases regression of atherosclerosis. 7,34 Can be difficult to tolerate due to GI side effects such as constipation and gas. 1 U.S.: $ (generic packets) (16 g/day). Canada: $ (Olestyr) (16 g/day). Colesevelam (WelChol [U.S.], Lodalis [Canada]) (Bile acid sequestrant) (FDA-approved for glycemic control in type 2 diabetes). 2 LDL : 15% to 19.1% (3.8 g/day). 2,8 HDL : 3% to 8.1% (3.8 g/day). 2,8 TG : 10% (3.8 g/day; about 20% when used with insulin or sulfonylureas). 2 10% to 16% (3.8 g/day). 2 3% to 7% (3.8 g/day). 2 None. Limited data with statins. Studied in combination with atorvastatin, lovastatin, pravastatin, and simvastatin. 2,10 Potential lower risk of GI side effects compared to cholestyramine and colestipol. 8,64 U.S.: $ (3.8 g/day). Canada: $ (3.8 g/day).
4 (PL Detail-Document #310703: Page 4 of11) Colestipol (Colestid, generic [U.S.]) (Bile acid sequestrant) LDL : 5% (2 g/day) to 26% (16 g/day). 1 HDL: no effect. 1 TG : 10% to 15% (2 to 16 g/day). 1 10% (5 g/day) to 12% (10 g/day). 11 Reduces progression of atherosclerosis and events when combined with niacin or lovastatin (events not a primary outcome). 50 Can be difficult to tolerate due to GI side effects such as constipation and gas. 8 U.S.: $ (10 g/day). Canada: $71.52 (10 g/day). Evolocumab d (Repatha) (PCSK9 inhibitor) LDL : 42% to 65%. 58,59,61,63 (Regardless of statin use.) See Lipid Effects column. Lowered LDL 34% to 38.5% more compared to ezetimibe. 58,60 The Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study (NCT ) is ongoing and is intended to provide an assessment of the cardiovascular benefit of evolocumab. 61 Very expensive. Consider with statins for HeFH and HoFH or clinical CVD requiring additional LDL lowering. 53,54 Administer by SubQ injection (allow to reach room temperature before injecting). 53,54 No dosage adjustment needed with mild to moderate renal or hepatic impairment. No safety data available for patients with severe renal or hepatic impairment. 53,54 No long-term safety data. U.S.: $ (140 mg every two weeks). Canada: $ (140 mg every two weeks).
5 (PL Detail-Document #310703: Page 5 of11) Ezetimibe (Zetia [U.S.], Ezetrol, generics [Canada]) (Cholesterol absorption inhibitor) (In U.S., available in combination with simvastatin [Vytorin] and atorvastatin [Liptruzet]). LDL : 18% (10 mg/day). 12,13 HDL : 1% (10 mg/day). 12,13 TG : 8%. 12,13 25%. 13 3%. 13 Further TG : 14%. 13 With simvastatin 20 mg, reduces first major atherosclerotic event in chronic renal disease [Level A]. 29 Adding ezetimibe to simvastatin 40 mg post-acs prevents one CV event for every 50 patients treated for 7 yrs vs simvastatin alone [Level A]. 30 Consider ezetimibe as a moderate-dose statin add-on for high-risk secondary prevention patients who can t tolerate a highintensity statin, or who don t get the expected 50% LDL reduction with a high-intensity statin. 49 U.S.: $ (10 mg/day). Canada: $50.81 (10 mg/day). (Vytorin [U.S.]: $ [10 mg/ 20 mg/day]). (Liptruzet [U.S.]: $ [10mg/20mg/day]). Fenofibrate (Tricor, Lofibra, Trilipix, Antara [U.S.], Lipidil EZ [Canada], others, generics) (Fibric acid) Continued LDL : 20.6% (145 mg). 15 HDL : 11% (145 mg). 15 TG : 23.5% to 54.5% (greatest drop in patients with highest triglycerides) (145 mg). 15 0% to 6% (200 mg) % to 17% (200 mg) Further TG : 20% to 32% (200 mg) Prevention of CV events in type 2 diabetes: did not reduce primary composite outcome (non-fatal MI or CV death). Improved outcomes included non-fatal MI (24% ), coronary revascularization (21% ), progression to albuminuria, and reduced laser treatments for First-line option for TG >10 mmol/l 39 (about 1000 mg/dl). Option for TG >500 mg/dl 38 or 5 to 10 mmol/l. 39 Option for low HDL. 39 Requires renal dose adjustment. 33,b Associated with reversible increase in serum creatinine. 33 Unclear risk of cholelithiasis. 51 In the U.S., FDA U.S.: $27.92 (48 mg/day). U.S.: $15.29 (145 mg/day). Canada: $29.53 (145 mg/day). Canada: $8.82 (200 mg/day).
6 (PL Detail-Document #310703: Page 6 of11) Fenofibrate, continued retinopathy. Nonsignificant increase in CV death. 31 As statin add-on, did not lower risk of non-fatal MI, non-fatal stroke, or CV death more than statin alone in patients with type 2 diabetes at high risk for CV disease. 32 indication for fenofibric acid (Trilipix) use with statins revoked in April 2016 due to lack of CV benefit. 57 Fenofibrate is still indicated as monotherapy for lipid lowering. 66 Preferred over gemfibrozil for use with statins for safety. 33 Gemfibrozil (Lopid [U.S.], generics) (Fibric acid) LDL: No effect. 21 HDL : 6% (1200 mg/day). 21 TG : 33% to 50% (greatest drop in patients with highest triglycerides) (1200 mg/day). 21,41 Further TG : 41%. 19 9%. 19 Primary prevention, men: reduced sudden cardiac death plus fatal/nonfatal MI (NNT = 71 over 5 years)[level A]. 20 Secondary prevention of nonfatal MI plus cardiac death in men with low HDL (NNT = 23 over 5 years)[level A]. 21 First-line option for TG >10 mmol/l 39 (about 1000 mg/dl). Option for TG >500 mg/dl 38 or 5 to 10 mmol/l. 39 Option for low HDL. 39 Requires renal dose adjustment. 33,b Avoid with statin. 33,39 No mortality benefit. 20,21 Unclear risk of cholelithiasis. 51 U.S.: $6.85 (1200 mg/day). Canada: $33.42 (1200 mg/day).
7 (PL Detail-Document #310703: Page 7 of11) Icosapent ethyl (Vascepa) (U.S. only) (EPA; about 1 g omega-3s/capsule) LDL: No effect. 46 HDL: No effect. 46 TG : 27%. 46 Further TG : 21.5% (4 g/day), 10.1% (2 g/day) % (4 g/day). 47 A study is underway to look at reduction in cardiovascular events with icosapent in patients taking a statin. 48 Option for TG ³500 mg/dl. 46 Safe for use with statin. 47 Use caution with fish or shellfish allergy. 46 U.S.: $ (4 g/day). Niacin (Niacor [IR; U.S. only], Niaspan [ER], Niaspan FCT [Canada]) In the U.S., niacin was available as a combo with lovastatin (Advicor) and simvastatin (Simcor). Both products voluntarily withdrawn from the market in December Continued LDL : 14% to 17% 2 g/day); % (niacin IR 1.5 g/day and Niaspan 1.5 g/day). 28 HDL : 22% to 26% (2 g/day Niaspan); % (niacin IR 1.5 g/day); 28 20% to 22% 1.5 g/day) TG : 20% to 50%. 25 8% 1 g/day); 31% 2 g/day). 9 23% 1 g/day); 27% 2 g/day). 9 Further TG : 24% 1 g/day); 27% 2 g/day). 9 As statin add-on, reduces carotid intima-media thickness (surrogate marker) as compared to ezetimibe as statin add-on in patients with lower HDL. 29 Secondary MI prevention: one less MI for every 30 patients treated for five years (Coronary Drug Project)[Level B]. 24 No CV event benefit from combo of niacin + statin vs statin alone in patients with wellcontrolled LDL, low HDL, and high TG. 40 Option for TG >500 mg/dl 38 (about 5 mmol/l). Raises HDL more than any other agent. Dose-dependent risk of hyperglycemia (especially in patients with type 2 diabetes) and liver toxicity. 24 No mortality benefit. 24 May increase risk of statin myopathy. 24 FDA indication for niacin ER use with statins revoked in April 2016 due to lack of CV benefit/safety. 57 In Canada, niacin is still indicated as monotherapy for dyslipidemia. 22,23 In the U.S., niacin IR U.S.: $19.48 (Niacor 1 g/day). U.S.: $ g/day). Canada: $ g/day). Canada: $43.53 FCT 1 g/day).
8 (PL Detail-Document #310703: Page 8 of11) Niacin, continued and ER are approved for monotherapy or for use with bile acid sequestrants. 24 Omega-3 ethyl esters (Lovaza) (U.S. only) (EPA/DHA; about 1 g omega-3s/capsule). LDL : 44.5% (4 g/day). 27 HDL : 9.1% (4 g/day). 27 TG : 45% (4 g/day). 27 LDL : 0.7% (4 g/day) % (4 g/day). 27 Further TG : 29.5% (4 g/day). 27 Secondary prevention: reduces cardiovascular death, sudden death, and combined endpoint of death, non-fatal MI, and non-fatal stroke [Level B]. 26 Secondary prevention in patients with, or at risk for, type 2 diabetes: did not reduce CV events. About half of patients were taking a statin. 42 Option for TG >500 mg/dl (about 5 mmol/l). 38 Safe for use with statin. 39 Associated with an increase in risk for recurrence of symptomatic atrial fibrillation or flutter within first three months of therapy. 27 Use with caution with fish or shellfish allergy. 27 U.S.: $ (4 g/day). a. U.S. cost is wholesale acquisition cost (WAC) b. Maximum daily dose if CrCl <60 ml/min: bezafibrate 200 mg, gemfibrozil 600 mg, and fenofibrate 67 mg. Avoid if CrCl <15 ml/min. 33 c. TG-lowering effects of niacin, omega-3-ethyl esters, and fibrates is greatest in patients with higher baseline TG levels d. Lipid levels off statin therapy may be required for prior authorization.
9 (PL Detail-Document #310703: Page 9 of 11) Users of this PL Detail-Document are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical judgments based on the content of this document. Our editors have researched the information with input from experts, government agencies, and national organizations. Information and internet links in this article were current as of the date of publication. Levels of Evidence In accordance with the trend towards Evidence-Based Medicine, we are citing the LEVEL OF EVIDENCE for the statements we publish. Level Definition A High-quality randomized controlled trial (RCT) High-quality meta-analysis (quantitative systematic review) B Nonrandomized clinical trial Nonquantitative systematic review Lower quality RCT Clinical cohort study Case-control study Historical control Epidemiologic study C Consensus Expert opinion D Anecdotal evidence In vitro or animal study Adapted from Siwek J, et al. How to write an evidence-based clinical review article. Am Fam Physician 2002;65: Project Leaders in preparation of this PL Detail- Document: Melanie Cupp, Pharm.D., BCPS (Original July 2015), Beth Bryant, Pharm.D., BCPS, Assistant Editor (May 2016 update) References 1. PL Detail Document, Ezetimibe s Role in Cardiovascular Risk Reduction. Pharmacist s Letter/Prescriber s Letter. January Product information for WelChol. Daiichi Sankyo. Parsippany, NJ January Pravastatin Multicenter Study Group II. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Arch Intern Med 1993;153: Pan HY, DeVault HR, Swites BJ, et al. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Ther 1990;48: Sprecher DL, Abrams J, Allen JW, et al. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med 1994;120: Rifkind BM. Lipid Research Clinics Coronary Primary Prevention Trial: results and implications. Am J Cardiol 1984;54:30C-34C. 7. Watts GF, Lewis B, Brunt JN, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas Atherosclerosis Regression Study (STARS). Lancet 1992;339: Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999;159: Wolfe ML, Vartanian SF, Ross JL, et al. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol 2001;87: Bays HE, Davidson M, Jones MR, Abby SL. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol 2006;97: Simons LA, Simons J, Parfitt A. Successful management of primary hypercholesterolaemia with simvastatin and low-dose colestipol. Med J Aust 1992;157: Product monograph for Ezetrol. Merck Canada Inc. Kirkland, QC H9H 4M7. March Product information for Zetia. Merck/Schering- Plough Pharmaceuticals. North Wales, PA August Probstfield JL, Rifkind BM. The Lipid Research Clinics Coronary Primary Prevention Trial: design, results, and implications. Eur J Clin Pharmacol 1991;40(Suppl 1):S Product information for Tricor. AbbVie Inc. North Chicago, IL February Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 2005;45: Vega GL, Ma PT, Cater NB, et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol 2003;91: Athyros VG, Papageorgiou AA, Athyrou VV, et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002;25: Murdock DK, Murdock AK, Murdock RW, et al. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. Am Heart J 1999;138: Product information for Lopid. Pfizer, Inc. New York, NY November Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-
10 (PL Detail-Document #310703: Page 10 of11) Density Lipoprotein Cholesterol Intervention Trial Study Group. New Engl J Med 1999;34: Product monograph for Niaspan. Sunovion Pharmaceuticals Canada Inc. Mississauga, ON L5N 2V8. October Product monograph for Niaspan FCT. Sunovion Pharmaceuticals Canada Inc. Mississauga, ON L5N 2V8. December Product information for Niaspan. Abbott Laboratories. North Chicago, IL April Anderson TJ, Gregoire J, Hegele RA, et al update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013;29: Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002;105: Product information for Lovaza. GlaxoSmithKline. Research Triangle Park, NC May Knopp RH, Alagona P, Davidson M, et al. Equivalent efficacy of a time-release form of niacin ) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998;47: Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377: Cannon CP, Blazing MA, Giugliano R, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015 Jun 3 [Epub ahead of print]. 31. Keech A, Simes RJ, Barter P, et al. Effects of longterm fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366: ACCORD Study Group, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362: Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol 2007;99:3C-18C. 34. Product information for cholestyramine. Upsher- Smith Laboratories, Inc. Maple Grove, MN April Product monograph for Bezalip SR. Tribute Pharma Canada Inc. Milton, ON L9T 2R1. March Pauciullo P, Borgnino C, Paoletti R, et al. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). Atherosclerosis 2000;150: Bezafibrate Infarction Prevention (BIP) Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000;102: Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011;123: Genest J, McPherson R, Frohlich J, et al Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol 2009;25: The AIM-HIGH Investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated lowdensity lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial. Am Heart J 2011;161: Product monograph for Teva-gemfibrozil. Teva Canada Limited. Toronto, ON M1B 2K9. June The ORIGIN Trial Investigators, Bosch J, Gerstein HC, et al. N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012;367: Miller M. Current perspectives on the management of hypertriglyceridemia. Am Heart J 2000;140: Skulas-Ray AC, Kris-Etherton PM, Harris WS, et al. Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. Am J Clin Nutr 2011;93: Bays H, Shah A, Dong Q, et al. Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups. Int J Clin Pract 2011;65: Product information for Vascepa. Catalent Pharma Solutions. St. Petersburg, FL June Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol 2012;110: Clinicaltrials.gov. A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin (REDUCE-IT). Last updated October 30, (Accessed June 2015). 49. Stone NJ, Robinson JG, Lichtenstein AH, et al ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25 Suppl 2):S Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipidlowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:
11 (PL Detail-Document #310703: Page 11 of 11) 51. Brown WV. Expert commentary: the safety of fibrates in lipid-lowering therapy. Am J Cardiol 2007;99(6A):19C-21C. 52. Product information for Praluent. Sanofi-Aventis U.S. Bridgewater, NJ October Product monograph for Repatha. Amgen Canada Inc. Mississauga, ON L5N 0A4. September Product information for Repatha. Amgen Inc. Thousand Oaks, CA September Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372: Navarese SP, Kolodziejczak M, Schulze V, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med 2015;163: U.S. Government Publishing Office. Withdrawal of approval of indications related to coadministration with statins in applications for niacin extendedrelease tablets and fenofibric acid delayed-release capsules. April 18, Federal Register;81(74): /pdf/ pdf. (Accessed April 29, 2016). 58. Koren MJ, Lundqvist P, Bolognese M, et al. Anti- PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol 2014;63: Stroes E, Colquhoun D, Sullivan D, et al. Anti- PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 2014;63: Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo controlled, phase 2 study. Lancet 2012;380: Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372: OptumRx. Advicor, Simcor product discontinuations. %20Withdrawal_Advicor_Simcor_ v2.pdf. (Accessed May 11, 2016). 63. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. New Engl J Med 2014;370: Brunetti L, DeSantis EH. Patient tolerance and acceptance of colesevelam hydrochloride: focus on type-2 diabetes mellitus. P T 2015;40: Merck. Merck statement on FDA advisory committee meeting on IMPROVE-IT study with Vytorin. December 14, (Accessed May 11, 2016). 66. Product information for Trilipix. AbbVie Inc. North Chicago, IL April Cite this document as follows: PL Detail-Document, Non- Lipid-Lowering Agents. Pharmacist s Letter/Prescriber s Letter. July Evidence and Recommendations You Can Trust 3120 West March Lane, Stockton, CA ~ TEL (209) ~ FAX (209) Copyright Ó 2015 by Therapeutic Research Center Subscribers to the Letter can get PL Detail-Documents, like this one, on any topic covered in any issue by going to or
Non-Statin Lipid-Lowering Agents M Holler - Last updated: 10/2016
Drug/Class Cholestyramine (Questran) Bile acid sequestrant Generic? Lipid Effects Y/N (monotherapy) Y LDL : 9% (4 g to 8 ; 21% (16 g to 20 ; 23% to 28% (>20 HDL : 4% to 8% (16 to 24 TG : 11% to 28% (4
More informationNon-Statin Lipid-Lowering Agents
This Clinical Resource gives subscribers additional insight related to the Recommendations published in September 2018 ~ Resource #340933 non Non- Lipid-Lowering Agents s are the lipid-lowering agents
More informationPCSK9 Agents Drug Class Prior Authorization Protocol
PCSK9 Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationEzetimibe s Role in Cardiovascular Risk Reduction
PL Detail-Document #310101 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER January 2015 Ezetimibe s Role
More informationDrug Class Monograph
Drug Class Monograph Class: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Drugs: Praluent (alirocumab), Repatha (evolocumab) Line of Business: Medi-Cal Effective Date: February 17, 2016
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2063-8 Program Prior Authorization/Medical Necessity Medication Repatha (evolocumab) P&T Approval Date 5/2015, 9/2015, 11/2015,
More informationHigh ( 50%) Restrictions mg 20-40mg PA; TS ⱡ 15 ⱡ
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/16, 5/15, 2/14, 5/12, LOB AFFECTED: Medi-Cal
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2062-8 Program Prior Authorization/Medical Necessity Medication Praluent (alirocumab) P&T Approval Date 5/2015, 8/2015, 9/2015,
More informationMaking War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes
More informationPCSK9 Inhibitors: Promise or Pitfall?
PCSK9 Inhibitors: Promise or Pitfall? Tracy Harlan, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics tracy harlan@uiowa.edu Tracy Harlan does not have any actual or potential
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationHigh ( 50%) Restrictions mg 20-40mg Simvastatin (Zocor) 10mg 20-40mg $1.66 Pravastatin (Pravachol) mg $6.
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/8/2018 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/17, 5/16, 5/15, 2/14, LOB AFFECTED: Medi-Cal
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationWhat Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment?
What Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment? Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director, Prevention Intervention Center University
More information( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )
005 6 69-74 40 mg/dl > 50 mg/dl) (00 mg/dl < 00 mg/dl(.6 mmol/l) 30-40% < 70 mg/dl 40 mg/dl 00 9 mg/dl fibric acid derivative niacin statin fibrate statin niacin ( ) ( Diabetes mellitus,
More informationB. Patient has not reached the percentage reduction goal with statin therapy
Managing Cardiovascular Risk: The Importance of Lowering LDL Cholesterol and Reaching Treatment Goals for LDL Cholesterol The Role of the Pharmacist Learning Objectives 1. Review the role of lipid levels
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationPharmacy Management Drug Policy
SUBJECT: ; Praluent (alirocumab), Repatha (evolocumab) POLICY NUMBER: Pharmacy-61 EFFECTIVE DATE: 8/15 LAST REVIEW DATE: 9/22/2017 If the member s subscriber contract excludes coverage for a specific service
More informationGet a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management
Get a Statin or Not? Treatment Strategies in Dyslipidemia Management Michelle Chu, PharmD, BCACP, CDE Assistant Professor of Clinical Pharmacy, USC School of Pharmacy Sahar Dagher, PharmD Virtual Care
More informationDYSLIPIDEMIA. Michael Brändle, Stefan Bilz
DYSLIPIDEMIA Michael Brändle, Stefan Bilz Cardiovascular risk in patients with DM Current guidelines with emphasis on patients with DM Familial Hypercholesterolemia PCSK9-inhibitors Primary Prevention
More informationMonth/Year of Review: September 2014 Date of Last Review: September 2013
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationPCSK9 Inhibitors DRUG POLICY BENEFIT APPLICATION
DRUG POLICY BENEFIT APPLICATION PCSK9 Inhibitors Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationEvolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors
Evolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina at Chapel Hill
More informationHyperlipidemia: Past and Present. Rebecca Khaimova, PharmD The Brooklyn Hospital Center
Hyperlipidemia: Past and Present Rebecca Khaimova, PharmD The Brooklyn Hospital Center Rkhaimova@tbh.org Conflicts of Interest None to disclose Learning Objectives for Pharmacist Describe the pathophysiology
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationSupplement Table 2. Categorization of Statin Intensity Based on Potential Low-Density Lipoprotein Cholesterol Reduction
Supplement: Tables Supplement Table 1. Study Eligibility Criteria Supplement Table 2. Categorization of Statin Intensity Based on Potential Low-Density Lipoprotein Cholesterol Reduction Supplement Table
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Statin Therapy Page 1 of 10 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Statin Therapy Prime Therapeutics will review Prior Authorization requests. Prior Authorization
More information4 th and Goal To Go How Low Should We Go? :
4 th and Goal To Go How Low Should We Go? : Evaluating New Lipid Lowering Therapies Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose
More informationPharmacy Policy Bulletin
Pharmacy Policy Bulletin Title: Policy #: PCSK9 inhibitors Rx.01.170 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract.
More informationCopyright 2017 by Sea Courses Inc.
Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or
More informationDrug Therapy Guidelines
Drug Therapy Guidelines PCSK9 Inhibitors: Praluent TM, Repatha TM Applicable Medical Benefit Effective: 5/1/18 Pharmacy- Formulary 1 x Next Review: 3/19 Pharmacy- Formulary 2 x Date of Origin: 10/9/15
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More informationPIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationPraluent (alirocumab)
Praluent (alirocumab) Policy Number: 5.01.600 Last Review: 06/2018 Origination: 07/2015 Next Review: 06/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Praluent
More informationAlirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials
Alirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials G. Kees Hovingh, 1 Richard Ceska, 2 Michael Louie, 3 Pascal Minini,
More informationManagement of Post-transplant hyperlipidemia
Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and
More informationNovel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy
LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,
More informationDoctor discussion guide:
Bring this printout to your next doctor s appointment. It will help you and your doctor work together to set goals for treatment, evaluate the success of your treatment, and reduce your risk of side effects.
More informationNew Horizons in Dyslipidemia Management in Primary Care
New Horizons in Dyslipidemia Management in Primary Care Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or
More informationWhat do the guidelines say about combination therapy?
What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More informationnicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck
Scottish Medicines Consortium Resubmission nicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck New formulation 6 January 2006 The Scottish Medicines Consortium
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationAdvances in Lipid Management
Advances in Lipid Management Kavita Sharma, MD Assistant Professor of Medicine, Division of Cardiology Clinical Director of the Lipid Management Clinics, The Ohio State University Wexner Medical Center
More informationSubject: Repatha (evolocumab) Original Effective Date: 09/28/2015. Policy Number: MCP-258 Revision Date(s): 5/4/16; 4/17/17
Subject: Repatha (evolocumab) Original Effective Date: 09/28/2015 Policy Number: MCP-258 Revision Date(s): 5/4/16; 4/17/17 Review Date(s): 5/4/2016, 4/17/2017, 7/10/2018 DISCLAIMER This Medical Policy
More informationClinical Policy: Evolocumab (Repatha) Reference Number: CP.CPA.269 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Repatha) Reference Number: CP.CPA.269 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationMOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
More informationLipid Guidelines Who, What, and How Low. Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute
Lipid Guidelines Who, What, and How Low Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute Disclosures! None Objectives! List factors used in screening for dyslipidemia
More informationCholesterol. Medicines To Help You
Medicines To Help You Cholesterol Use this guide to help you talk to your doctor, pharmacist, or nurse about your cholesterol medicines. The guide lists all of the FDA-approved products now available to
More informationWhat s our starting point? New Lipid-Lowering Drugs: PCSK9 Inhibitors. Why You Should Care. Outline ATPIII Guidelines 1
New Lipid-Lowering Drugs: Inhibitors Blockbusters or Bust? Jody Mallicoat, BS, PharmD PGY1 Pharmacy Resident OSF Saint Francis Medical Center, Peoria, IL What s our starting point? Had you heard of inhibitors
More informationAntihyperlipidemic Drugs
Antihyperlipidemic Drugs Hyperlipidemias. Hyperlipoproteinemias. Hyperlipemia. Hypercholestrolemia. Direct relationship with acute pancreatitis and atherosclerosis Structure Lipoprotein Particles Types
More informationLipids & Hypertension Update
Lipids & Hypertension Update No financial disclosures Michael W. Cullen, MD, FACC Senior Associate Consultant, Assistant Professor of Medicine Mayo Clinic Department of Cardiovascular Diseases 34 th Annual
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.16.08 Subject: Repatha Page: 1 of 8 Last Review Date: September 18, 2015 Repatha Description Repatha
More informationEVOLOCUMAB Generic Brand HICL GCN Exception/Other EVOLOCUMAB REPATHA 42378
Generic Brand HICL GCN Exception/Other EVOLOCUMAB REPATHA 42378 This drug requires a written request for prior authorization. All requests for Repatha (evolocumab) require review by a pharmacist prior
More informationPCSK9 Inhibitors: Changing the Landscape of Lipid-Lowering Therapy
PCSK9 Inhibitors: Changing the Landscape of Lipid-Lowering Therapy http://parriscardio.theangelheartcenter.com/wp-content/uploads/2013/03/heart-disease-prevention.jpg Jennifer Jiang, PharmD PGY1 Pharmacy
More informationRepatha (evolocumab) Policy Number: Last Review: 06/2018 Origination: 07/2015 Next Review: 06/2019
Repatha (evolocumab) Policy Number: 5.01.601 Last Review: 06/2018 Origination: 07/2015 Next Review: 06/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Repatha
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationClinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date:
Clinical Policy: (Juxtapid) Reference Number: ERX.SPA.170 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationDoctor discussion guide:
Doctor discussion guide: MAnaging Cholesterol Bring this printout to your next doctor s appointment. It will help you and your doctor work together to set goals for treatment, evaluate the success of your
More informationIt is the policy of health plans affiliated with PA Health & Wellness that Vytorin is medically necessary when the following criteria are met:
Clinical Policy: Ezetimibe and Simvastatin (Vytorin) Reference Number: PA.CP.PMN.77 Effective Date: 02.01.17 Last Review Date: 07.18 Revision Log Description Ezetimibe/simvastatin (Vytorin ) contains ezetimibe,
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject PCSK9 Inhibitors Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 9 References... 9 Effective Date... 01/15/2018
More informationManaging Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures
Managing Dyslipidemia in 2018 Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS Professor of Medicine (Cardiology) Co-Director, Cardiac Transplant Clinic; Associate Chair, Health Research Ethics Boards;
More informationLDL-C treatment goals were introduced in the first National
Point/Counterpoint Counterpoint: Low-Density Lipoprotein Cholesterol Targets Are Not Needed in Lipid Treatment Guidelines Jennifer G. Robinson, Kausik Ray Abstract On the basis of accumulating evidence,
More informationEvolocumab for the treatment of primary hypercholesterolaemia and mixed dyslipidaemia
Evolocumab for the treatment of primary hypercholesterolaemia and mixed dyslipidaemia Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) November 2015 2015 Summary Evolocumab (Repatha,
More informationCholesterol Treatment Update
Cholesterol Treatment Update Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public Health Disclosure:
More informationClass Update PCSK9 Inhibitors
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationESC, ACC/AHA and Malaysian CPG Guidelines on lipids Statins Introduction to non-statins Guideline recommendations for non-statins Clinical trials of
ESC, ACC/AHA and Malaysian CPG Guidelines on lipids Statins Introduction to non-statins Guideline recommendations for non-statins Clinical trials of non-statin drugs Non-statin vs placebo Non-statin vs
More informationAchieving Lipid Goals: 2008 Update. Laura Hansen, Pharm.D. Associate Professor, University of Colorado School of Pharmacy
Achieving Lipid Goals: 2008 Update Laura Hansen, Pharm.D. Associate Professor, University of Colorado School of Pharmacy Discuss relationship between lipid values and coronary events Evaluate clinical
More informationDrug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin
Drug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin Final Report Update 5 November 2009 This report reviews information about the comparative
More informationClass Update PCSK9 Inhibitors
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationManagement of Lipid Levels and Cardiovascular Disease in HIV-Infected Individuals: Just Give Them a Statin?
Perspective Management of Lipid Levels and Cardiovascular Disease in HIV-Infected Individuals: Just Give Them a Statin? Current guidelines for managing cholesterol to reduce cardiovascular disease (CVD)
More informationEffect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes
Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, CM Ballantyne, R Somaratne, J Legg, SM Wasserman, R Scott, MJ Koren, and EA Stein for
More informationTuesday, October 18 3:30 p.m. 5:30 p.m. Convention Center: Rooms 315 & 316
Ambulatory Care PRN Focus Session New Developments in Hypertension and Dyslipidemia Management Activity No. 0217-0000-11-101-L01-P (Application-Based Activity) Tuesday, October 18 3:30 p.m. 5:30 p.m. Convention
More informationDyslipidemia Management - Summary. Adults at any age with the following risk factors should be screened for lipids at any age:
Dyslipidemia Management - Summary How do I assess Dyslipidemia? Screening of plasma lipids is recommended in adult men 40 and women that are 50 years of age or who are postmenopausal. Adults at any age
More informationClinical Policy: Evolocumab (Repatha) Reference Number: ERX.SPMN.184 Effective Date: 01/2017
Clinical Policy: (Repatha) Reference Number: ERX.SPMN.184 Effective Date: 01/2017 Last Review Date: Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.
More informationNew Guidelines in Dyslipidemia Management
The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Repatha) Reference Number: HIM.PA.SP46 Effective Date: 01.01.18 Last Review Date: Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 8 Last Review Date: December 2, 2016 Repatha Description Repatha (evolocumab)
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More informationGoal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects (GAUSS): Results from a
Goal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects (GAUSS): Results from a Randomized, d Double-blind, bli Placebo- Controlled Study Evan A. Stein 1, David Sullivan 2,
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More informationREPATHA (PCSK9 INHIBITORS)
REPATHA (PCSK9 INHIBITS) Indications: PCSK9 Inhibitors are indicated for treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease as
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationADMINISTRATIVE POLICY AND PROCEDURE
ADMINISTRATIVE POLICY PROCEDURE Policy #: Subject: PCSK9 INHIBITS (ex: Repatha) Section: Care Management Effective Date: January 1, 2015 Revision Date(s): NA Review Date(s): NA Responsible Parties: Patryce
More informationPCSK9 Inhibitors for Lowering Cholesterol: Ready for Prime Time?
Original Article Thomas Knickelbine, MD, FACC, FSCCT, FSCAI From: Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN Address for correspondence: Thomas Knickelbine, MD, FACC,
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationCardiovascular outcomes trials with non-statin lipid-lowering drugs in diabetes
Cardiovascular outcomes trials with non-statin lipid-lowering drugs in diabetes FARIHA NAEEM, GERARD MCKAY, MILES FISHER REVIEW Abstract Statin therapy is proven to reduce cardiovascular morbidity and
More informationPCSK9 Inhibitors Praluent (Alirocumab) and Repatha (Evolocumab) For the Treatment of Familial Hypercholesterolemia
PCSK9 Inhibitors Praluent (Alirocumab) and Repatha (Evolocumab) For the Treatment of Familial Hypercholesterolemia Policy Number: Original Effective Date: MM.04.037 08/01/2016 Line(s) of Business: HMO;
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 9 Last Review Date: September 15, 2017 Repatha Description Repatha
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationTuesday, October 18 3:30 p.m. 5:30 p.m. Convention Center: Rooms 315 & 316
Ambulatory Care PRN Focus Session New Developments in Hypertension and Dyslipidemia Management Activity No. 0217-0000-11-101-L01-P (Application-Based Activity) Tuesday, October 18 3:30 p.m. 5:30 p.m. Convention
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 9 Last Review Date: November 30, 2018 Repatha Description Repatha (evolocumab)
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationLipid Goals: Update on their Status
Butler University Digital Commons @ Butler University Scholarship and Professional Work COPHS College of Pharmacy & Health Sciences 2013 Lipid Goals: Update on their Status Katie Axford Eliza Dy Sarah
More informationCoronary heart disease is the leading cause of death in
PHARMACOLOGY NOTES Ezetimibe (Zetia): a new type of lipid-lowering agent JIGNA PATEL, PHARMD CANDIDATE, VALERIE SHEEHAN, PHARMD, AND CHERYLE GURK-TURNER, RPH Coronary heart disease is the leading cause
More information